Company intelligence / Profile preview

Oncorena AB

Ownership: Private
Development stage: Other

Overview

Oncorena’s lead program ONC175 (synthetic orellanine) has entered Phase I/II clinical trials for metastatic renal cell carcinoma in dialysis-dependent patients. The first patient was treated in August 2023 at Karolinska University Hospital without complications. The trial evaluates safety, tolerability, pharmacokinetics, and anti-tumor efficacy. FDA IND approval was granted in March 2025 to expand the study into the US and Europe. If successful, the indication may be expanded to all mRCC patients not responding to first-line therapy.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

orellanine

Beyond the preview

Go deeper on Oncorena AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncorena AB.